Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

FDA Approves Ponatinib for Chronic-Phase CML

The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for ponatinib to treat adults with chronic-phase chronic myeloid leukemia...
On location

Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection

Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...
On location

Asciminib Beats Bosutinib in Treatment-Resistant Chronic Myeloid Leukemia

Asciminib, a first-in-class allosteric inhibitor that Specifically Targets ABL Myristoyl Pocket (STAMP), was more effective at achieving major molecular response (MMR) than bosutinib in...

Study Identifies Key Mutations That Promote Stem Cell Growth and Increase Leukemia Risk

In a report published in Nature, researchers linked three genetic loci to the increased proliferation of hematopoietic stem cells (HSCs), which may subsequently increase...

Anthony Mato: LOXO-305 Demonstrates Efficacy in Patients With CLL/SLL

Anthony Mato, MD, shares findings from a phase I/II trial evaluating LOXO-305 in patients with heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Andreas Hochhaus: Asciminib vs. Bosutinib in Chronic Myeloid Leukemia

Andreas Hochhaus, MD, discusses results from a phase I study suggesting asciminib may have superior efficacy to bosutinib in patients with heavily pretreated chronic...

Mogamulizumab Demonstrates Antitumor Activity in Adult T-Cell Leukemia/Lymphoma

Nearly two-thirds of patients with adult T-cell leukemia-lymphoma (ATLL) responded to treatment with mogamulizumab as a single agent or as part of a treatment...

Study Supports Earlier, More Frequent Use of Hospice in Older Patients With Hematologic Malignancies

Earlier and more frequent hospice use may be associated with a lower probability of inpatient death and a reduction in aggressive care at end...
On location

Interim Results of Randomized Comparison of Ponatinib Starting Doses in Chronic-Phase CML

Response-based ponatinib dosing demonstrated clinical benefit in patients with resistant chronic-phase chronic myeloid leukemia (CML) with rate of arterial occlusive (AO) events that did...
WIB_icon

Lenzilumab Demonstrates Clinical Benefit in Patients With Chronic Myelomonocytic Leukemia

A phase I study found that lenzilumab, an engineered human IgG1K monoclonal antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), was associated with a clinical...
Advertisement

Current Issue

January 2021 Annual Meeting Edition

This issue features highlights from the 2020 ASH Annual Meeting, a look at patient holiday gift customs around the world, and more.

Block title